Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical setting

22 Jun 2017

Abstract excerpt

OBJECTIVES: The primary aim of this study was to compare the screening performance for trisomy 21 (T21) between combined first-trimester screening (cFTS) with referral for invasive testing at a T21 risk ≥ 1 in 300, and contingent screening consisting of referral for invasive testing at a cFTS-T21 risk ≥ 1 in 100 and referral for cell-free DNA (cfDNA) testing at a cFTS-T21 risk between 1 in 100 and 1 in 1000....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Assisted Reproductive Technology and Twin Pregnancy
Share to Gestational Trophoblastic Disease Studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28640470
DOI: 10.1002/uog.17562

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical settingPMID 28640470Read ↗

First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testingSemantic proximity Read ↗

Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot studySemantic proximity Read ↗

Screening for trisomies 21, 18 and 13 by cell‐free <scp>DNA</scp> analysis of maternal blood at 10–11 weeks' gestation and the combined test at 11–13 weeksSemantic proximity Read ↗

Analysis of cell‐free <scp>DNA</scp> in maternal blood in screening for fetal aneuploidies: updated meta‐analysisSemantic proximity Read ↗

Combined First Trimester Screening and Cell-Free Fetal DNA – “Next Generation Screening”Semantic proximity Read ↗

Routine first‐trimester screening for fetal trisomies in twin pregnancy: cell‐free DNA test contingent on results from combined testSemantic proximity Read ↗

Cell‐free <scp>DNA</scp> testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10–14 weeks and meta‐analysisSemantic proximity Read ↗

Prenatal diagnostic testing and atypical chromosome abnormalities following combined first‐trimester screening: implications for contingent models of non‐invasive prenatal testingSemantic proximity Read ↗

First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA TestingSemantic proximity Read ↗

Analysis of cell‐free DNA in maternal blood in screening for aneuploidies: updated meta‐analysisSemantic proximity Read ↗

Clinical implementation of routine screening for fetal trisomies in the UK NHS : cell‐free DNA test contingent on results from first‐trimester combined testSemantic proximity Read ↗

Clinical Perspective of Cell-Free DNA Testing for Fetal AneuploidiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.